![logo](/logos/ATRA.webp)
Atara Biotherapeutics, Inc.
NASDAQ:ATRA
9.47 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Atara Biotherapeutics, Inc. |
Symbool | ATRA |
Munteenheid | USD |
Prijs | 9.47 |
Beurswaarde | 46,545,524 |
Dividendpercentage | 0% |
52-weken bereik | 4.975 - 49 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Pascal Touchon D.V.M. |
Website | https://www.atarabio.com |
An error occurred while fetching data.
Over Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)